• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    AbbVie (NY: ABBV )

    211.55 -0.51 (-0.24%)
    Official Closing Price Updated: 4:10 PM EDT, Mar 13, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about AbbVie

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    75 76 Next >
    Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
    The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug. 
    Via Investor's Business Daily
    Worried About a Market Meltdown? 2 Dividend Stocks to Own Forever.
    Via The Motley Fool
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You?
    Vanguard has some excellent dividend ETFs, but they are right for different investors. 
    Via The Motley Fool
    Topics ETFs
    AbbVie Options Trading: A Deep Dive into Market Sentiment
    Via Benzinga
    13 Analysts Have This To Say About AbbVie
    Via Benzinga
    $1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
    Via Benzinga
    Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
    As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad... 
    Via StockStory
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
    There's a lot going on for investors. 
    Via The Motley Fool
    This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
    Via The Motley Fool
    ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week
    Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among... 
    Via Stocktwits
    3 Stocks Breaking Out Right Now
    These three stocks are touching new all-time highs. 
    Via Talk Markets
    Topics Stocks / Equities
    Is the SPDR S&P 500 ETF Trust the Smartest Investment You Can Make Today?
    Via The Motley Fool
    Topics ETFs Stocks
    Exposures US Equities
    3 Cheap Stocks to Buy With Your Tax Refund Check
    Via The Motley Fool
    2 Dividend Stocks to Buy for a Lifetime of Passive Income
    Via The Motley Fool
    Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
    As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. 
    Via StockStory
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
    AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market. 
    Via Benzinga
    AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
    This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1. 
    Via Investor's Business Daily
    These Vanguard ETFs Show Where the Smart Money Is Moving Now
    Via The Motley Fool
    Topics ETFs
    4 Sectors That Thrive When Inflation Runs Hot
    Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value 
    Via MarketBeat
    Topics Economy World Trade
    Exposures Interest Rates Tariff
    3 Reasons ABBV is Risky and 1 Stock to Buy Instead
    AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the S&P 500 has returned 5.1%. 
    Via StockStory
    Topics Stocks
    Exposures US Equities
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
    Via The Motley Fool
    2 High-Yield Dividend ETFs to Buy to Generate Passive Income
    With yields ranging between 3.6% and 7.3%, these dividend ETFs are great bets for generating passive income. 
    Via The Motley Fool
    Topics ETFs
    Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
    Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer 
    Via MarketBeat
    Topics Death
    Exposures Death
    Large Cap Biopharmaceutical Metrics And Performance Q1 2025
    Tariffs could have big impact on earnings in 2025. 
    Via Talk Markets
    Topics Stocks / Equities
    2 Magnificent Dividend Growth Stocks to Load Up On Right Now
    Via The Motley Fool
    4 Stocks and 1 Exchange-Traded Fund (ETF) I Can't Stop Buying
    Five great investments for any portfolio. 
    Via The Motley Fool
    What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
    Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. 
    Via StockStory
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    75 76 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.